HEALTH OF WOMAN. 2016.3(109):18–23; doi 10.15574/HW.2016.109.18 
 

Treatment of stress-induced luteal phase deficiency (LPD) 
 

Tatarchuk T. F., Cossey N. V., Tutchenko T. N.

Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Kiev 
 

The luteal phase deficiency (LPD) is a condition manifested by progesterone deficiency, shortening of the luteal phase (less than 11 days) and delay endometrial maturation from the phase of the cycle more than 2 days. Chronic stress is one of the most frequent causes of development of this violation. The study involved three groups of women with stress-induced miscarriage. Group 1 (n=35) women received treatment with the drug Cyclodiene + herbal anti-depressant hyperacid. Group 2 (n=41) is a similar treatment + Duphaston. Group 3 (n=42) – Dufaston in monotherapy. According to the study the level of perception of stress in these patients was significantly higher than in women with burdened reproductive history. They also had lower levels of FSH, LH and progesterone with an increased level of cortisol. These changes correlated with the level of personal perception of stress. After a 3-month course of treatment for best results decrease the level of stressful tension observed in group 2 (combination of an antidepressant with Cyclodiene and Duphaston). This was reflected in faster and more significant reduction in the severity of the level of stressful tension in comparison with groups 1 and 2. In addition, there was a marginally significant decrease in the activation of stress-realizing systems: reducing the level of prolactin and cortisol with increasing concentrations of progesterone and normalization of cyclic production of gonadotropin.

Key words: luteal phase deficiency (LPD), a comprehensive anti-stress therapy.

REFERENCES

1. Dal J. 2005. Power Doppler ultrasound studies of ovarian, uterine, and endometrial blood flow in regularly menstruating women with respect to luteal phase defects. Fertility and Sterility 84;1:224–227. http://dx.doi.org/10.1016/j.fertnstert.2004.12.059; PMid:16009189

2. Takasaki Akihisa, Tamur Hiroshi, Taniguchi Ken. 2000. Luteal blood flow and luteal function. Journal of Ovarian Research 2:1.

3. Devoto L. 2000. The human corpus luteum: life cycle and function in natural cycles. Fertil Steril. 02(3):1067–1070.

4. Marchenko LA. 2000. Zheltoe telo. Mehanizmyi formirovaniya i regressa. Ginekologiya dlya prakticheskih vrachey 5:2.

5. Bulavenko OB. 2008. Nedostatnist liuteinovoi fazy: klinika, diahnostyka ta likuvannia: Avtoref. dys. d-ra med. nauk: spets. 14.01.01. «Akusherstvo ta hinekolohiia». DU «IPAH NAMN Ukrainy». K:37.

6. Sidelnikova BM. 2005. Privyichnaya poterya beremennosti. M:303.

7. Chayka BK, Demina TN, Kolomiytseva AG i dr. 2003. Nevyinashivanie beremennosti: problemyi i taktika lecheniya. Pod red. TN Deminoy. Sevastopol, Veber:261.

8. Loboda MB, Babov KD, Stebliuk VV. 2004. Khvoroby dezadaptatsii v praktytsi vidnovliuvalnoi medytsyny. K:300.

9. Chrousos GP. 2007. An integrated view of the stress response and stress-related behavioral and/or somatic disorders. Hans Selye Centennial Lecture, Proceedings of the Second World Conference on Stress. Budapest.

10. Chatterjee A, Chatterjee R. 2000. How stress affects female reproduction: An overview. Biomedical Research 20(2):70–83.

11. Hamberger L, Hahlin BM. Luteotropic and Luteolytic Factors Regulating Human Corpus Luteum Function. Annals of the New York Academy of Sciences 541, Issue. In Vitro Fertilization and Other Assisted Reproduction:485–407. http://dx.doi.org/10.1111/j.1749-6632.1988.tb22285.x

12. Tatarchuk TF, Bulavenko OV, Tutchenko TM. 2008. Optimizatsiya metodov lecheniya nedostatochnosti lyuteinovoy fazyi u zhenschin reproduktivnogo vozrasta na fone giperprolaktinemii. Zdorov’ya zhInki 2:90–96.

13. Tutchenko TM. 2010. PregravIdarna pIdgotovka zhInok zI stres-Indukovanim nevinoshuvannyam vagItnostI v anamnezI. Avtoref. dis. kand. med. nauk: spets. 14.01.01. «Akusherstvo ta gInekologIya». DU «IPAG NAMN UkraYini». K:20.

14. Kellie Breen M, Heather Billings J, Elizabeth Wagenmaker R et al. 2005. Endocrine Basis for Disruptive Effects of Cortisol on Preovulatory Events. Endocrinology 146(4):2107–2115. http://dx.doi.org/10.1210/en.2004-1457; PMid:15625239

15. Chrousos GP. 2007. Neuroendocrinology of stress and female reproductive function. Proceedings of the 5th European Congress of Reproductive Immunology. Berlin.

16. Chrousos GP. 2000. Stress and Disorders of the Stress System. Nat. Rev. Endocrinol. 5:374–381. http://dx.doi.org/10.1038/nrendo.2009.106; PMid:19488073

17. Nakamura K, Sheps S, Arck P. 2008. Stress and reproductive failure: past notions, present insights and future directions. J Assist Reprod Genet. 25(2–3):47–62. http://dx.doi.org/10.1007/s10815-008-9206-5; PMid:18274890 PMCid:PMC2582116

18. Smetnik VP, Butareva LB. 2005. Opyit primeneniya fitopreparata «Tsiklodinon» («Agnukaston») u patsientok s nedostatochnostyu funktsii zheltogo tela i giperprolaktinemiey. Problemyi reproduktsii 5:1-4.